Oncology Vol 30 No 12

Breast Cancer After Hodgkin Lymphoma: The Price of Success

December 15, 2016

Curative therapy, including chest RT for Hodgkin lymphoma, is associated with a definitively increased risk of breast cancer, most often manifesting approximately 20 years after treatment. These breast cancers tend to be more aggressive, with greater frequency of hormone receptor negativity and potential HER2 positivity.

POINT: The Role of Stem Cell Transplantation in Mantle Cell Lymphoma

December 15, 2016

The landscape of mantle cell lymphoma is clearly evolving, due to the availability of new treatment options incorporating novel biologic agents. To optimize therapy, we should build on what has been accomplished over the last 3 decades.